New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:08 EDTIMMUImmunomedics announces presentation of epratuzumab data
Immunomedics announced that scientific data on epratuzumab, an investigational therapy for the treatment of systemic lupus erythematosus, also known as lupus, will be presented at the European League Against Rheumatism 2014 Annual Congress to be held in Paris, France. Epratuzumab is an investigational medicine in Phase III clinical development for the treatment of SLE. Epratuzumab is a monoclonal antibody that targets CD22. Epratuzumab is not approved for the treatment of SLE by any regulatory authority worldwide. Immunomedics has granted UCB exclusive worldwide rights to develop, market, and sell epratuzumab for all autoimmune disease indications.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
10:24 EDTIMMUHigh option volume stocks
High option volume stocks: TIVO TIF ASHR OCR TGP JEC CEQP UTX PWRD IMMU
November 21, 2014
08:35 EDTIMMUImmunomedics granted FDA orphan drug designation for veltuzumab
Immunomedics announced that the Office of Orphan Products Development of the FDA has granted orphan status for the use of veltuzumab, the company's humanized anti-CD20 antibody, for the treatment of pemphigus. Pemphigus is a debilitating and potentially fatal autoimmune blistering disease of the skin and mucous membranes. In most cases, irregularly-shaped, painful erosions or lesions initially develop in the mucous membranes lining the inside of the mouth. To maintain disease control typically requires long-term exposure to corticosteroids and other drugs which suppress the immune system and may themselves contribute to osteoporosis, septicemia, and other serious adverse events seen in this population.
November 20, 2014
08:37 EDTIMMUImmunomedics says partial response achieved for 11 months in IMMU-130 trial
Subscribe for More Information
November 18, 2014
17:09 EDTIMMUImmunomedics veltuzumab designated for orphan status
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use